I
iSTAR Medical
Minimally-invasive ophthalmic implants for treating glaucoma
About iSTAR Medical
iSTAR Medical, founded in 2010, is a clinical-stage medical technology company specializing in developing and commercializing minimally invasive ophthalmic implants to treat glaucoma. The company's headquarters are in Wavre, Belgium, with an international presence that includes an office in the US. iSTAR Medical's mission is to become a leader in Micro-Invasive Glaucoma Surgery (MIGS) by providing advanced eye care solutions. The company was founded by Michel Alvarez, who has since left the company. Since 2014, the company has been led by CEO Michel Vanbrabant, who brought over two decades of experience from leadership roles at companies like Guidant Inc., St. Jude Medical, and Reva Medical Inc. His background includes a Master's Degree in Business Engineering from the Solvay School of Economics and Management and an Executive MBA from Columbia Business School.
The company's core business revolves around its flagship product, MINIject, a MIGS device designed for patients with open-angle glaucoma. MINIject is engineered to reduce intraocular pressure (IOP) by creating a new pathway for fluid to drain from the eye, targeting the supraciliary space. What sets MINIject apart is its proprietary STAR material, a soft, flexible, medical-grade silicone with a micro-porous structure. This material is designed to be anti-fibrotic and anti-inflammatory, promoting bio-integration with the surrounding tissue to ensure long-term efficacy and minimize complications. The STAR material was originally developed at the University of Washington in Seattle, and iSTAR Medical holds an exclusive license for its use in ophthalmology. The business model focuses on the development, manufacturing, and sale of the MINIject device to ophthalmic surgeons and hospitals. The company has received market approval for MINIject in Europe, the UK, Switzerland, and Australia and is pursuing FDA approval in the US through its pivotal STAR-V clinical trial.
iSTAR Medical has secured significant funding through multiple rounds to support its research, development, and commercialization efforts. The company has raised a total of $60.8M over 4 rounds. Key funding milestones include a Series B round of €10 million in 2016 and a substantial Series C round of €40.1 million in 2019. This later round was led by Life Sciences Partners (LSP) and Gimv, with participation from investors like Earlybird, Capricorn Partners, and SRIW. In July 2022, iSTAR Medical announced a strategic alliance with AbbVie to develop and commercialize MINIject, although this partnership was terminated in April 2025, with iSTAR continuing as an independent entity.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 31.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Ophthalmology, medical implants, Glaucoma, Hard Tech, DT and LS, science-based
- Technology
- Hardware
- Business model
- Manufacturing
- Client focus
- B2B, B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| CONVERTIBLEOther financing | Jul 2022 | $60M | — | AbbVie · Abbvie Biotech Ventures | ↗ |
| SERIES COther financing | Sep 2019 | $44M | $176M | Capricorn Partners · Earlybird Venture Capital · SFPIM · BNP Paribas Fortis | — |
Growth signals
Latest recorded traffic for iSTAR Medical is 1.4K monthly website visits, down 36.4% over the last three months. iSTAR Medical's team declined 18.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
iSTAR Medical in the Wavre ecosystem
The iSTAR Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Capricorn Partners
Wallonie Entreprendre
Namur Invest
SFPIM
AbbVie
Abbvie Biotech Ventures
Series B and later4 investors entered at this stage
Gimv
EQT Life Sciences
Earlybird Venture Capital
BNP Paribas Fortis
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about iSTAR Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See iSTAR Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








